RVMDRevolution Medicines, Inc.
$189.76+336% 1Y
$189.76
$42.5152 weeks$216.19
Who owns RVMD
682 institutions reported holding RVMD for 2026Q2, together 108% of the company, more than the 505 a quarter earlier.
682
Institutions reporting a position · as of 2026Q2 · up from 505 the quarter before
- Shares held by institutions
- 213.8M
Shares held by institutions · 108% of the company · long US equity positions only, as reported on Form 13F
- Reported value
- $40.1B
Reported value · at Jun 30, 2026 prices, not today's
- Top 5 holders
- 35%
Top 5 holders · of the whole company, between five filers
Details›
- Reporting quarter2026-06-30
- 2026Q2
- Quarters on record
- 26
- New positions
- 239
- Positions exited
- 65
- Added to
- 226
- Reduced
- 145
- Top 10 holdersof the company
- 56%
- Shares sold shortsettled Sep 15, 2026
- 9.7M
- Short interestof shares outstanding
- 4.9%
- Days to coverat the average daily volume
- 7.2
- Change in the short positionsince the Aug 31, 2026 count
- −0.60%
| Quarter | Filers | Shares | Reported value |
|---|---|---|---|
| 2026Q2 | 682 | 213.8M | $40.1B |
| 2026Q1 | 505 | 198.1M | $19.0B |
| 2025Q4 | 381 | 199.3M | $15.9B |
| 2025Q3 | 319 | 191.8M | $8.95B |
| 2025Q2 | 304 | 190.7M | $7.02B |
| 2025Q1 | 279 | 192.4M | $6.82B |
| 2024Q4 | 278 | 192.9M | $8.44B |
| 2024Q3 | 250 | 170.5M | $7.73B |
| 2024Q2 | 221 | 168.3M | $6.53B |
| 2024Q1 | 209 | 160.6M | $5.18B |
| 2023Q4 | 183 | 159.9M | $4.59B |
| 2023Q3 | 166 | 112.3M | $3.11B |
| 2023Q2 | 138 | 112.0M | $2.99B |
| 2023Q1 | 150 | 108.1M | $2.34B |
| 2022Q4 | 135 | 88.2M | $2.10B |
| 2022Q3 | 141 | 88.4M | $1.74B |
| Holder | Shares | % of company | Value |
|---|---|---|---|
| VANGUARD GROUP INC | 18.9M | 9.6% | $3.55B |
| BlackRock Inc. | 13.7M | 6.9% | $2.56B |
| FARALLON CAPITAL MANAGEMENT LLC | 13.6M | 6.8% | $2.54B |
| FMR LLC | 12.2M | 6.2% | $2.28B |
| BAKER BROS. ADVISORS LP | 11.4M | 5.8% | $2.14B |
| Jupiter Topco LLC | 10.7M | 5.4% | $2.01B |
| Darwin Global Management, Ltd. | 10.6M | 5.4% | $2.05B |
| Nextech Invest Ltd. | 7.6M | 3.8% | $1.42B |
| Paradigm Biocapital Advisors LP | 6.4M | 3.2% | $1.19B |
| UBS Group AG | 5.4M | 2.8% | $1.02B |
| Settlement | Shares short | Of shares outstanding | Days to cover |
|---|---|---|---|
| Sep 15, 2026 | 9.7M | 4.9% | 7.2 |
| Aug 31, 2026 | 9.7M | 4.9% | 4.7 |
| Aug 14, 2026 | 9.7M | 4.9% | 6.4 |
| Jul 31, 2026 | 11.5M | 5.8% | 6.3 |
| Jul 15, 2026 | 14.0M | 7.1% | 6.8 |
| Jun 30, 2026 | 12.9M | 6.5% | 3.0 |
| Jun 15, 2026 | 12.3M | 6.2% | 4.3 |
| May 29, 2026 | 11.6M | 5.9% | 4.2 |
| May 15, 2026 | 11.1M | 5.6% | 4.7 |
| Apr 30, 2026 | 12.8M | 6.5% | 3.3 |
| Apr 15, 2026 | 13.4M | 6.8% | 3.0 |
| Mar 31, 2026 | 15.4M | 7.8% | 7.9 |
SEC Form 13F data sets (DERA bulk files). 13F is quarterly, filed up to 45 days late, and covers long US equity positions only, no shorts, no derivatives, nothing held below the reporting threshold. The short position is FINRA's consolidated count for each twice-monthly settlement date, as a share of shares outstanding.
opening the register…